MyoKardia (NASDAQ:MYOK) has reacquired U.S. royalty rights to mavacamten and MYK-224 from Sanofi in exchange for $50M in upfront cash plus an additional $30M by June 30, 2020. Under the terms of their former agreement, Sanofi was eligible to receive royalties of 5 – 10% on U.S. sales.
Enrollment in the Phase 3 EXPLORER-HCM study evaluating mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) should be completed in about a month. Topline data should be available in Q2 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.